Clinical Trial Update: A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing pralsetinib to standard of care in RET-mutated medullary thyroid cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Pralsetinib (pralsetinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Medullary Thyroid Cancer | Phase 3 | Status: WITHDRAWN